PARACETAMOL INDUCED ANGIOEDEMA
Sir, This communication describes a 4-year-old boy with a presumed viral infection who developed allergic rash and angioedema probably related to paracetamol exposure. The child presented with history of fever and minute maculopapular rash, which began on the buttocks and spread to involve the entire body (day 1). On day 3, he received 2 doses of syrup paracetamol (acetaminophen, 15 mg/kg/dose) from his general practitioner. Within an hour of receiving the dose, the child developed edema of the lips, along with massive dermal edema which initially involved the periorbital region and the face and later spread to involve the trunk and the limbs. The edema was accompanied by rash in the form of discolored patches, which was morphologically distinct from the maculopapular rash which the child had developed on day 1. Unaware of the association between rash and the paracetamol, the patient continued to receive the drug for high fever (20 mg/kg/dose, twice daily -day 4) on the advice of the practitioner. No other medication was given. On the following day (day 5), he was hospitalized under our care due to abdominal pain, vomiting, and discolored patches (rash) on the face, hands, and feet. On examination, the child's vital parameters were stable. Edema and the rash involved the entire body, including the upper lip and scrotum. The throat and conjunctivae were congested. The systemic examination did not reveal any abnormal finding. The child's hematological and biochemical parameters were within normal limits. Chest radiograph revealed prominence of broncho-vascular markings, and ultrasound of the abdomen did not reveal any abnormality. Tests for hepatitis B, leptospirosis, and dengue infections were nonreactive.
Suspecting an adverse event, the administration of paracetamol was stopped. The child received injection hydrocortisone (15 mg/kg/d, once daily for 2 days), along with a single dose of 1 cc chlorpheniramine maleate. The edema subsided within 4 to 5 hours after the child received hydrocortisone. He was treated with syrup hydroxyzine (1 mg/kg/d), syrup erythromycin (30 mg/kg/d in 3 divided doses), application of calamine lotion and tepid sponging for 3 days. The fever and rash subsided over the next 4 days, and the child was discharged on day 9. Causality analysis (Naranjo's algorithm) [1] gave a score of 6 (probable reaction).
Paracetamol is a widely used antipyretic agent with an excellent safety record. However, in a few patients, skin and respiratory symptoms, immediate urticaria, angioedema, [2] Þ xed drug reactions, [3] and anaphylaxis [4] have been reported to be associated with exposure to the drug. The worsening of manifestations on continued exposure and amelioration of manifestations following drug withdrawal in this case point towards a probable causal role of paracetamol. Since the character of the rash on exposure to paracetamol (urticaria/angioedema) was quite different from the initial rash (maculopapular), the former is unlikely to represent accentuation of the rash associated with presumed viral infection.
In susceptible patients, angioedema has an abrupt onset and commonly involves the eyes, lips, hands, and the feet. The edema may also involve the throat (leading to hoarseness and dyspnea) and the GI tract (leading to vomiting, diarrhea followed by abdominal pain and anorexia). [5] Nonsteroidal anti-inflammatory drug (NSAID including aspirin) use has a higher propensity to be associated with urticaria, angioedema, and pruritus caused by non-allergic reactions due to inhibition of isoform 1 of cyclooxygenase (COX 1). Although the exact mechanism for occurrence of angioedema is yet to be fully elucidated, it is presumed to be a hypersensitivity reaction (allergic or non-allergic) to a toxic metabolite of paracetamol. Despite paracetamol being metabolized to highly reactive metabolites, these reactions are only infrequently reported because it is only a weak inhibitor of prostaglandin synthesis. Most patients (though not all) with hypersensitivity to paracetamol also have hypersensitivity to NSAIDs. [2] But paracetamol is associated with hypersensitivity reactions in less than 5% of those who are known to be sensitive to NSAIDs. [6] This limits the choice of antipyretic agents that can be administered to patients with paracetamol hypersensitivity. Given the cross-reactivity with NSAIDs, they should be used with caution in these subjects, and parents may have to rely more on physical measures (like tepid sponging) for controlling fever in such children. 
QUETIAPINE INDUCED MYOCLONUS
Sir, Quetiapine is a dibenzothiazepine derivative atypical anti-psychotic and has been suggested to have a lower risk of movement disorder adverse effects. Few reports of myoclonus induced by quetipaine are available in the literature. So, here we report 2 young females who developed myoclonic jerks while on quetiapine.
Miss D, a 19-year-old female presented to us with history suggestive of manic episode for the last 2 months. Her past history also revealed history of 2 GTCS around 6 years back for which no treatment was sought. Her family and personal history were non signiÞ cant. She was started on quetiapine gradually increased to 300 mg per day over a week and lorazepam 2 mg at night. She showed improvement in her symptoms over the next 2 weeks. After this, the dose was increased to 400 mg per day. After 2 days of this, she developed sudden abrupt jerks lasting for less than a second, especially involving the right upper extremity. These movements would at times be so frequent that she even dropped the things in her hand. An EEG revealed intermittent bilateral polyspike discharges. Her biochemical investigations and MRI brain were normal. The dose of quetiapine was decreased to 200 mg per day and after about 1 week the patient did not have these jerky movements. EEG after 10 days of this was normal. Quetiapine was then stopped and she was started on oxcarbamazepine and lorazepam and improved in 1 month.
In another case, a 17-year-old female presented with history suggestive of schizophrenia for the past 5 years with no response to risperidone and haloperidol. Her past, family and personal history were non-contributory. She was started on clozapine. However she developed myoclonic jerks on 250 mg of clozapine. Hence clozapine was tapered and stopped over 1 week and quetiapine was started and increased to 500 mg per day over the next 3 weeks, with some improvement in symptoms. The dose was increased to 600 mg per day after 5 weeks of quetiapine initiation. After 3 days of this, the patient developed abrupt jerky movements of palate and upper limbs. Her EEG revealed frequent, intermittent bilateral spike discharges, and slow wave complexes in the precentral regions, reflecting epileptic tendency. All biochemical tests and MRI brain were normal. The dose of quetiapine was reduced to 400 mg per day and the patient showed improvement in these jerky movements in about 5 days. An EEG 10 days after decreasing quetiapine showed no abnormal discharges. Triß uperazine in the dose of 20 mg was then added.
Both our cases developed jerking on quetiapine therapy, which abated on decreasing the dose of quetiapine. In the second case, possibility of clozapine being responsible again for the myoclonus was not considered as it was stopped 4 weeks prior to the jerks. The reports of finding EEG abnormality in such patients have been contradictory in previous
